质母细胞瘤分泌的C1QL1调节瘤微管扩张和神经突触修剪,以驱动恶性突触形成和复发
Chaoqiong Ding1, Jiayi Dong1, Zhenzhong Pan1
1Sichuan University Chengdu, Sichuan China.
Cancer discovery
|February 26, 2026
概括
瘤细胞在瘤微管上形成恶性突触,驱动大脑瘤的生长. 一种名为C1QL1的蛋白质通过削减正常突触来促进这一过程,但Rac1抑制剂可以阻止这一过程,提供一种新的质母细胞瘤治疗策略.
科学领域:
- 神经瘤学神经瘤学
- 细胞神经科学 细胞神经科学
- 分子生物学分子生物学
背景情况:
- 质母细胞瘤 (GBM) 细胞在瘤微管 (TMs) 上形成恶性突触,有助于透生长和复发.
- 对GBM细胞和神经元交叉声调的精确机制,有利于恶性而不是正常突触,尚不清楚.
研究的目的:
- 为了确定GBM细胞和神经元之间的交叉声调节的关键分子媒介.
- 阐明这些介质在TM扩张和恶性突触形成中的作用.
- 探索针对GBM复发的治疗策略.
主要方法:
- 研究了质瘤分泌的C1QL1在GBM-神经元和GBM-GBM交叉声调中的作用.
- 检查了C1QL1与神经元和GBM细胞上的受体BAI3的结合.
- 分析了Rac1激活及其对细胞骨重组和突触形成的下游影响.
- 在临床前模型中使用了新的Rac1抑制剂进行向治疗.
主要成果:
- 质瘤分泌的C1QL1充当一个关键的信使,调解交叉通话.
- 结合BAI3的C1QL1激活Rac1,导致正常的突触修剪和TM外生长.
- 这一过程促进恶性突触的形成和质瘤网络的发展.
- 有针对性的Rac1抑制有效地阻止了C1QL1介导的突触修剪和TM形成.
结论:
- C1QL1-BAI3-Rac1信号通过促进恶性突触形成和TM扩张驱动GBM透.
- 针对Rac1提供了一个有希望的治疗策略,通过同时破坏TM和质瘤诱导的突触修剪来抑制GBM复发.
更多相关视频
10:08Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions
Published on: February 24, 2021
7.0K
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
4.0K
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
